Search global stocks & ETFs...Ctrl K
Learn Mode
Globus Medical IncGMED
$80.39
-$0.13 (-0.161%)
$81.23
$0.84 (1.049%)
GMED
Stock Profile
08-05
Recommended Metric
Score Card
Explore Scores Tab
4.07
Good
Valuation Score
Key Score
5.00
Very Good
Management
3.00
Average
Growth
3.00
Average
Profitability
3.00
Average
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$80.39
Baseline
High
$129.15
▲
60.65%
Avg
$112.83
▲
40.35%
Low
$92.92
▲
15.59%
Analyst Ratings based on 21 Analysts
Strong Buy
419%
Buy
1152%
Hold
629%
Sell
000%
Strong Sell
000%
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 6,000 full-time employees. The company went IPO on 2012-03-08. The firm provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The firm offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. The company separates its products and services into two major categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities.Read More
Stock News
View All Updates
News100%Bullish
Globus Medical Inc - A (NYSE:GMED) Screens as an Affordable Growth Opportunity with Solid Fundamentals
1dChartMill
Madison Small Cap Fund Sold Globus Medical (GMED) as Valuation Exceeded
2dYahoo
Veeva Expands Safety Suite Footprint With UCB Pharmacovigilance Deal
2dYahoo
Veeva Expands Safety Suite Footprint With UCB Pharmacovigilance Deal
2dZacks
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
2dYahoo
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
2dZacks
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
2dYahoo
Should You Continue to Hold EW Stock in Your Portfolio?
2dYahoo
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
3dYahoo
Hinge Health Expands HingeSelect to Offer End-to-End MSK Surgical Care
3dYahoo
Is It Time To Reassess Globus Medical (GMED) After Its Recent Share Price Recovery?
3dYahoo
A Look At Globus Medical (GMED) Valuation After Q1 Beat And Upgraded Full-Year Guidance
3dYahoo
Globus Medical (NYSE:GMED) Shines in Navellier's Little Book Growth Stock Screen
3dChartMill
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
4dYahoo
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
4dYahoo
AMN Expands Language Services Portfolio With Jaide Health Deal
4dYahoo
Here is Why Globus Medical (GMED) is One of the Most Profitable Growth Stocks to Buy
4dYahoo
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
5dYahoo
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
5dYahoo
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
5dYahoo
2 Reasons to Watch GMED and 1 to Stay Cautious
5dYahoo
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
6dYahoo
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
6dYahoo
Here's Why You Should Retain NVST Stock in Your Portfolio for Now
6dYahoo
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
6dYahoo
Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?
6dYahoo
Globus Medical, Inc. (GMED) A Cheap Robotics Stock Firing on Earnings and Revenue Growth
6dYahoo
1 Profitable Stock with Solid Fundamentals and 2 Facing Headwinds
6dYahoo
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
1wYahoo
GMED or PEN: Which Is the Better Value Stock Right Now?
1wYahoo
COO Stock Rises on Q2 Earnings Beat, FY26 Revenue Guidance Trimmed
1wYahoo
FMS Launches kinexus Digital Platform for Home Dialysis Care
1wYahoo
2 Mid-Cap Stocks with Exciting Potential and 1 Facing Challenges
1wYahoo
GE HealthCare Gains FDA Clearance for AI Radiation Planning Software
1wYahoo
Here's Why You Should Retain DexCom Stock in Your Portfolio
1wYahoo
VEEV Stock Down Despite Q1 Earnings & Revenues Beat Estimates
1wYahoo
Integer Holdings 2026 Outlook: Drivers, Risks, Valuation
1wYahoo
Globus Medical (GMED) Is Down 5.6% After Pivoting Excelsius Robotics To Leasing Model - Has The Bull Case Changed?
1wYahoo
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
1wYahoo
Here's How Financial Strength Remains a Key Advantage for GMED
1wYahoo
Stryker Launches TPX HD Power Tool for Complex Orthopedic Procedures
1wYahoo
Is Omnicell Stock a Smart Addition to Your Portfolio Now?
1wYahoo
Here's Why You Should Add PacBio Stock to Your Portfolio Now
1wYahoo
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
1wYahoo
Globus Medical: Obtaining My Backing Again
1wSeekingAlpha
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
1wYahoo
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
1wYahoo
Globus Medical Rethinks Robotics Revenue Model As FDA Approvals Broaden Story
1wYahoo
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
1wYahoo
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
1wYahoo